Morocco - Women's share of population ages 15+ living with HIV (%)

Women's share of population ages 15+ living with HIV (%) in Morocco was 44.10 as of 2020. Its highest value over the past 30 years was 50.70 in 1990, while its lowest value was 44.10 in 2020.

Definition: Prevalence of HIV is the percentage of people who are infected with HIV. Female rate is as a percentage of the total population ages 15+ who are living with HIV.

Source: UNAIDS estimates.

See also:

Year Value
1990 50.70
1991 49.50
1992 48.30
1993 47.40
1994 46.80
1995 46.40
1996 46.20
1997 46.10
1998 46.20
1999 46.20
2000 46.40
2001 46.60
2002 46.80
2003 47.10
2004 47.30
2005 47.40
2006 47.60
2007 47.60
2008 47.60
2009 47.40
2010 47.20
2011 46.90
2012 46.50
2013 46.20
2014 45.90
2015 45.60
2016 45.40
2017 45.20
2018 44.90
2019 44.50
2020 44.10

Limitations and Exceptions: The limited availability of data on health status is a major constraint in assessing the health situation in developing countries. Surveillance data are lacking for many major public health concerns. Estimates of prevalence and incidence are available for some diseases but are often unreliable and incomplete. National health authorities differ widely in capacity and willingness to collect or report information.

Statistical Concept and Methodology: HIV prevalence rates reflect the rate of HIV infection in each country's population. Low national prevalence rates can be misleading, however. They often disguise epidemics that are initially concentrated in certain localities or population groups and threaten to spill over into the wider population. In many developing countries most new infections occur in young adults, with young women especially vulnerable. Data on HIV are from the Joint United Nations Programme on HIV/AIDS (UNAIDS). Changes in procedures and assumptions for estimating the data and better coordination with countries have resulted in improved estimates of HIV and AIDS. The models, which are routinely updated, track the course of HIV epidemics and their impact, making full use of information in HIV prevalence trends from surveillance data as well as survey data. The models take into account reduced infectivity among people receiving antiretroviral therapy (which is having a larger impact on HIV prevalence and allowing HIV-positive people to live longer) and allow for changes in urbanization over time in generalized epidemics. The estimates include plausibility bounds, which reflect the certainty associated with each of the estimates.

Aggregation method: Weighted average

Periodicity: Annual

Classification

Topic: Health Indicators

Sub-Topic: Risk factors